Reinhart Partners LLC. Has $44.01 Million Stock Holdings in Encompass Health Corporation $EHC

Reinhart Partners LLC. raised its stake in Encompass Health Corporation (NYSE:EHC) by 1.9% in the second quarter, Holdings Channel reports. The firm owned 435,362 shares of the company’s stock after acquiring an additional 8,162 shares during the quarter. Reinhart Partners LLC.’s holdings in Encompass Health were worth $44,008,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. WPG Advisers LLC grew its stake in shares of Encompass Health by 73.3% in the fourth quarter. WPG Advisers LLC now owns 324 shares of the company’s stock valued at $34,000 after buying an additional 137 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Encompass Health in the fourth quarter valued at $37,000. Caitong International Asset Management Co. Ltd grew its position in shares of Encompass Health by 36,200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock valued at $46,000 after acquiring an additional 362 shares during the period. Assetmark Inc. grew its position in shares of Encompass Health by 89.6% in the 1st quarter. Assetmark Inc. now owns 455 shares of the company’s stock valued at $44,000 after acquiring an additional 215 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Encompass Health during the 4th quarter worth about $55,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Up 0.5%

Encompass Health stock opened at $125.39 on Friday. The stock has a market cap of $12.44 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.67 and a beta of 0.72. The company has a quick ratio of 1.17, a current ratio of 1.19 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a twelve month low of $92.77 and a twelve month high of $127.99. The company’s 50-day moving average price is $106.91 and its two-hundred day moving average price is $104.59.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%.The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, analysts expect that Encompass Health Corporation will post 6.08 EPS for the current year.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be paid a $0.21 dividend. This is a boost from Encompass Health’s previous quarterly dividend of $0.19. The ex-dividend date is Thursday, October 1st. This represents a $0.84 annualized dividend and a yield of 0.7%. Encompass Health’s dividend payout ratio is presently 12.69%.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the transaction, the executive vice president directly owned 24,755 shares of the company’s stock, valued at $2,588,382.80. This represents a 2.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on EHC shares. TD Cowen initiated coverage on Encompass Health in a report on Thursday, May 28th. They set a “buy” rating and a $125.00 price target for the company. UBS Group upped their price objective on Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings downgraded Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. Leerink Partners set a $152.00 target price on Encompass Health in a report on Friday, May 22nd. Finally, Barclays increased their price target on Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $146.57.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.